CeriBell, Inc. is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining highly portable and rapidly deployable hardware with artificial intelligence-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared (510(k)) for indicating suspected seizure activity and utilized in intensive care units and emergency rooms across the United States. Clarity, its machine learning algorithm, continuously interprets a patient’s EEG waveforms and displays actionable insights regarding seizure activity on the recorder. Its EEG portal is a cloud-based portal that enables real-time remote access to a patient’s EEG data.
BörsenkürzelCBLL
Name des UnternehmensCeriBell Inc
IPO-datumOct 11, 2024
Gegründet am2014
CEOMs. Xingjuan (Jane) Chao, Ph.D.
Anzahl der mitarbeiter281
WertpapierartOrdinary Share
GeschäftsjahresendeOct 11
Addresse360 N. Pastoria Avenue
StadtSUNNYVALE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94085
Telefon18004360826
Websitehttps://ceribell.com/
BörsenkürzelCBLL
IPO-datumOct 11, 2024
Gegründet am2014
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten